Bharat Biotech submits phase 3 trial data of COVAXIN vaccine to WHO for approval
On Wednesday, India’s indigenous COVID vaccine ‘Covaxin’ manufacturer Bharat Biotech has submitted its phase-3 clinical trial results to the World Health Organization (WHO) for clearance. Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for evaluation of the WHO’s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin.
Credits – Source – https://ift.tt/3gxvtrZ
The post Bharat Biotech submits phase 3 trial data of COVAXIN vaccine to WHO for approval appeared first on Stay in Gurgaon.
Comments
Post a Comment